Tripartite motif-containing 67 (TRIM67), an E3 ubiquitin ligase, belongs to the TRIM protein family. The relationship between TRIM67 and tumorigenesis is not fully clear. Here, we elucidated TRIM67 function in non-small cell lung cancer (NSCLC). TRIM67 immunostaining results were correlated with clinicopathological features. Moreover, the function of TRIM67 in cultured NSCLC cells was evaluated by MTT, colony formation, and Transwell assays. TRIM67 expression was associated with tumor size, lymph node metastasis, p-TNM stage, cancer cell differentiation, and poor prognosis. We altered TRIM67 expression in A549 and H1299 cell lines, and the results showed that TRIM67 promoted cell proliferation, migration, invasion and EMT by positively regulating the Notch pathway. Collectively, the results showed that TRIM67 promotes NSCLC progression through the Notch pathway and that TRIM67 expression is associated with clinicopathological features, indicating that TRIM67 may play an important role in promoting the development of NSCLC and could be applied as not only an important prognostic biomarker but also a therapeutic target in NSCLC.
Introduction
Lung cancer is one of the leading causes of death worldwide, is closely associated with lung disease, and its incidence continues to rise [1] [2] [3] [4] [5] . The 5-year survival rate remains at 15% and the prognosis of non-small cell lung cancer (NSCLC) patients is mainly related to tumor metastasis, which is related to transcriptional regulation of some key genes [5, [6] [7] [8] . Therefore, understanding the mechanism of NSCLC progression is very important for the treatment of NSCLC.
The Notch pathway is involved in development and cell proliferation, differentiation, and apoptosis. As a result of its multiple effects on tissue homeostasis and cancer, this signaling pathway has attracted increasing attention as a potential therapeutic target.
Notch proteins belong to a highly conserved family of cell surface receptors. Ligand binding leads to the complex proteolysis of these receptors by the γ-secretase complex, followed by translocation of the active intracellular incision nuclei and transcriptional activation domains [9] . Notch signaling is activated by a ligand that binds to a receptor, initiating an intercellular communication system of five ligands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged-1, and Jagged-2) and four receptors (Notch1-4). Ligand binding causes conformational changes of Notch, resulting in the exposure of the S2 site and sequence cleavage by the protease, disintegrase, a member of the metalloproteinase family and gamma secretase complex, to release the Notch intracellular domain Ivyspring International Publisher (NICD). Finally, NICD is transferred to the nucleus, where it induces the target gene [10, 11] Yitong et al.
2018).
Tripartite motif-containing (TRIM) proteins are characterized by a common domain consisting of a RING finger, one or two B-box motifs and a coiled-coil motif, and are involved in many biological processes, including innate immunity, viral infection, cancer, and development [12] [13] [14] . TRIM67 belongs to the tripartite motif (TRIM) protein family [15] . Therefore, TRIM67 may be a specific E3 ubiquitin ligase, which is significant for target protein ubiquitin-dependent degradation or stabilization [16] . TRIM67 was reported to be associated with the nervous system [17] [18] [19] , but its function in tumors has not been reported.
In this study, we demonstrated that TRIM67 promotes the proliferation, migration, invasion and EMT of NSCLC cells through the Notch pathway. Additionally, we detected the expression of TRIM67 in NSCLC tissues and cell lines by immunohistochemistry and western blotting and altered the expression of TRIM67 in NSCLC cells to study the variations of the cancer-related phenotype and determine its role in NSCLC.
Methods

Specimens and patient data
These assays were performed as described previously [5] . All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, and informed consent was obtained from all individual participants.
Immunohistochemistry
These assays were performed as described previously [5] .
Cell culture
Plasmid construction, transfection, and administration of Notch pathway inhibitors
According to the manufacturer's instructions, Lipofectamine 3000 reagent was largely used for cell transfection (Invitrogen, Carlsbad, CA, USA). We used short hairpin RNA (shRNA) targeting TRIM67 to knockdown the expression of TRIM67, which was cloned into the SGU6 vector (Sangon Biotech, Shanghai), for 48 h. For upregulating the expression of TRIM67, we used TRIM67-expression plasmid and the corresponding empty pCMVNeo04 vector (LongqianBiotech, Shanghai, China).
To inhibit Notch signaling, we treated cells with 4 µM DAPT (MedChemExpress, Monmouth Junction, NJ, USA), a γ-secretase inhibitor blocking the Notch pathway, in dimethyl sulfoxide (DMSO), and an equal amount of DMSO was accordingly supplied to cells as a control 24 h after transfection.
Immunocytochemistry
Lung cancer cells cultured in 24-well plates for 24 h were immobilized in paraformaldehyde (4%) for 15 min and permeated with 0.1% Triton X-100 for 10 min. Next, the cells were washed with PBS and then blocked in bovine serum albumin (5%) for 1 h and incubated with anti-TRIM67 antibody (1:50) at 4 °C overnight. Thereafter, the cells were incubated with the secondary antibody, TRITC binding antibody, for 2 h; cell nuclei were re-stained with DAPI, and images were captured using the Olympus FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).
Western blotting
Western blotting revealed several functional proteins that directly affect cell migration, cell invasion [28] [29] [30] , and cell proliferation [31, 32] . Cellular proteins were extracted using lysis buffer (P0013; Beyotime Biosciences, Shanghai, China) containing protease-inhibitor cocktail (B14002; Biotool, Shanghai, China). Proteins were quantified using the Bradford method. Approximately 60 µg of each protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 10% gels, transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), blocked in 5% skim milk (232100; Becton Dickenson, Franklin Lakes, NJ, USA) at 28 °C, and incubated with antibodies (Table  1 ) overnight at 4 °C. Membranes were then washed and incubated with horseradish peroxidase-conjugated anti-mouse/rabbit IgG (1:2000; ZSGB-BIO, Beijing, China) at 37 °C for 2 h. Finally, immunoreactivity was detected using the BioImaging system (UVP, Inc., Upland, CA, USA).
Cell migration and invasion analyses
Cell proliferation and colony formation assays
These assays were performed as described previously [33] .
Statistical analysis
Statistical analyses were mostly performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Survival rates were analyzed by the Kaplan-Meier method and compared by the log rank test (Kaplan-Meier Plotter. Available from URL: http://www.kmplot.com /analysis/index.php?p=service&cancer=lung) [34] . Student's t-test was used to analyze statistically significant differences between the expression of TRIM67 and clinical features, and P < 0.05 was considered statistically significant.
Results
TRIM67 correlates with clinicopathological characteristics and poor prognosis
Immunofluorescence analysis of seven NSCLC cells showed that TRIM67 was localized in both the cytoplasm and nucleus ( Fig. 1c ). Moreover, immunohistochemical analysis showed that TRIM67 expression in low-differentiated NSCLC tissues was significantly higher than that in high-differentiated NSCLC tissues ( Fig. 1a ). Next, we investigated whether TRIM67 protein levels were associated with clinical features. The results showed that TRIM67 levels were positively correlated with differentiation (P < 0.001), tumor size (P = 0.018), lymph node metastasis (P < 0.001), and pathological TNM stage (P < 0.001), but not age (P = 0.424), sex (P = 0.328), and histological type (P = 0.514) as shown in Table 2 . Moreover, high expression of TRIM67 was associated with lower survival in NSCLC patients according to the Kaplan-Meier database (Fig. 1b ). Based on the above results, we suggest that TRIM67 might have an important effect on the biological functions of NSCLC. Western blot analysis was also performed to determine the expression of TRIM67 in HBE normal bronchial epithelial cells and six NSCLC cell lines (Fig. 1d) , and then we selected A549 and H1299 cell lines for subsequent studies because TRIM67 was moderately expressed in these two cell lines. 
TRIM67 expression promotes migration and invasion of NSCLC cells
Based on the previously mentioned findings, we next studied the effect of TRIM67 protein in NSCLC. To this end, we altered TRIM67 expression by downregulation or upregulation in both A549 and H1299 cell lines. We found that TRIM67 knockdown inhibited the migration and invasion of A549 and H1299 cells as compared to that of control cells through Transwell assays, whereas migration and invasion were promoted by TRIM67 overexpression (P < 0.05; Fig. 2a ). Further, alteration of TRIM67 protein expression had an effect on the expression of proteins related to cell migration and invasion, consistent with the aforementioned results. Transfection efficiency was also examined by western blotting 48 h post-transfection. Upon TRIM67 upregulation, the levels of RhoA, RhoC, and matrix metalloproteinase (MMP)-9 increased, whereas its downregulation exerted the opposite effect ( Fig. 2b and c). Consistent with our immunohistochemical results, these results suggested that TRIM67 enhances the migration and invasion of NSCLC cells.
TRIM67 expression promotes the proliferation of NSCLC cells
We next analyzed the effect of TRIM67 expression on cell proliferation. Colony formation analysis clearly demonstrated that TRIM67 expression and colony-formation ability of tumor cells were positively correlated in A549 and H1299 cells; specifically, downregulation inhibited clone formation, whereas upregulation had the opposite effect, when compared to that in respective control groups (Fig. 3a) . Subsequent MTT assays revealed that upregulation of TRIM67 expression enhanced cell proliferation, whereas downregulation had an opposite effect in A549 cells (Fig. 3b) , similar to the observation in H1299 cells (Fig. 3c ). Consistent with these observations, TRIM67 overexpression promoted the proliferation of NSCLC cells, which also agreed with our immunohistochemical results showing that TRIM67 levels are associated with tumor size. We next analyzed the proliferation-related proteins, and the results showed that when TRIM67 was upregulated, the expression of c-Myc was also upregulated, whereas that of P21 was downregulated; knockdown of TRIM67 had the opposite effect on these proteins in both A549 and H1299 cells ( Fig. 3d  and e ). 
TRIM67 positively regulates the expression of proteins related to epithelial-mesenchymal transition (EMT)
To elucidate the mechanism by which TRIM67 enhances the migration/invasion of lung cancer cells, we detected the expression of EMT-related proteins by western blotting. Results showed that increased TRIM67 expression enhanced N-cadherin, vimentin, Snail, and slug expression, but suppressed E-cadherin in A549 cells (Fig. 4a) , similar to the observation in H1299 cells (Fig. 4b) . These results revealed that TRIM67 can affect the migration and invasion of NSCLC cells by promoting epithelial-mesenchymal transition(EMT). 
TRIM67 regulates migration, invasion, cell proliferation, and EMT of NSCLC cells through the Notch pathway
We clarified the role of TRIM67 in NSCLC cell migration, invasion, and proliferation and then investigated the biological mechanisms related to these effects. The Notch pathway is involved in the development of several cancers by influencing the expression of EMT-related proteins and other factors found to be altered by TRIM67 modulation; therefore, we examined whether TRIM67 is involved in the regulation of Notch signaling in NSCLC cells. Western blotting results showed that TRIM67 knockdown downregulated the expression of Notch1, Jagged1, and NICD in A549 and H1299 cell lines, whereas overexpression had the opposite effects ( Fig.  5a and b) . To investigate whether the function of TRIM67 was mediated through the Notch pathway, we used the inhibitor, DAPT, which inhibits NICD expression. DAPT inhibited cell migration, invasion, and proliferation in A549 and H1299 cells transfected with p-trim67 ( Fig. 5c and 6a) , and the effect of TRIM67 overexpression on protein expression of A549 and H1299 cells was reversed ( Fig. 6b and c) . These results indicated that activation of the Notch pathway contributes to TRIM67-mediated migration, invasion, and proliferation in NSCLC cells.
Discussion
TRIM67 is a protein that belongs to TRIM family and is localized to the cytoplasm and nucleus. Here, we demonstrated that TRIM67 is expressed in NSCLC and multiple lung cancer cell lines.
In this study, we showed that the expression of TRIM67 was associated with a range of clinicopathological features, such as tumor size, differentiation, lymph node metastasis, p-TNM staging, and prognosis. We also demonstrated that TRIM67 promotes the proliferation, migration, invasion and EMT of NSCLC cells through the Notch pathway and the expression of downstream proteins such as RhoA, RhoC, MMP-9, P21, c-myc, and EMT-related markers [17, 20, 21] , thereby influencing the malignant behavior of tumor cells. However, the mechanisms involved in these functions are unclear, and further studies are needed.
The role of the Notch pathway in cancers has been determined according to the effect of Notch pathway on cell proliferation, migration, and invasion [22] [23] [24] [25] [26] . In the present study, we demonstrated that TRIM67 overexpression can upregulate Notch1, Jagged1, and NICD. NICD translocates to the nucleus, where it binds to several transcription factors and regulates the expression of target genes. The γ-secretase inhibitor DAPT blocks the Notch pathway by reducing the formation of NICD [27] . When we added DAPT, the effects of TRIM67 on NSCLC functions were reversed, which confirmed that TRIM67 functions through the regulation of Notch signaling. However, in this study, we did not confirm how TRIM67 acts on the Notch pathway. TRIM67 is an E3 ubiquitin ligase, so we speculate that this pathway is activated by ubiquitination of Notch pathway-inhibiting proteins. Even if this is true, it is still unclear which domain and binding site of TRIM67 are involved in this process, and thus further studies are needed.
In conclusion, our study demonstrated that TRIM67 plays a significant role in NSCLC via the Notch pathway, suggesting that TRIM67 might be a candidate prognostic biomarker and possible therapeutic target for NSCLC. Even though further studies are needed to determine the functions of TRIM67 in these biological processes, our results offer significant views and reflections about the functions and mechanisms of TRIM67 in tumorigenesis.
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